Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

Mounjaro, which is the brand name for tirzepatide, was shown to be even more powerful than Ozempic in a recent study with adults who were overweight or obese.

Eli Lilly's Mounjaro is significantly more effective than Novo Nordisk's Ozempic in producing weight loss, a real-world study found

New diabetes drug Mounjaro is more effective for weight loss that the popular drug Ozempic, an analysis found. The analysis, conducted by Truveta Research, found that patients taking Eli Lilly’s diabetes drug Mounjaro were “significantly more likely” to experience 5 percent,